Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.53 |
| ▸ | NRAS | P01111 | 3/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239521 | 0.92 | FLT3 (0.52) | FLT3NRASIRAK4GABRG2GABRB3 | |
| SCHEMBL10239886 | 0.91 | FLT3 (0.53) | FLT3NRASIRAK4KDRCSF1R | |
| SCHEMBL376827 | 0.91 | FLT3 (0.51) | FLT3NRASIRAK4GABRG2GABRB3 | |
| SCHEMBL10239089 | 0.90 | FLT3 (0.48) | FLT3NRASIRAK4KDRCSF1R | |
| SCHEMBL10238379 | 0.90 | FLT3 (0.48) | FLT3NRASIRAK4KDRCSF1R | |
| SCHEMBL12553537 | 0.89 | FLT3 (0.47) | FLT3NRASIRAK4KDRCSF1R | |
| SCHEMBL10239824 | 0.87 | IRAK4 (0.51) | FLT3IRAK4 | |
| SCHEMBL10239870 | 0.86 | FLT3 (0.56) | FLT3NRASIRAK4KDRCSF1R | |
| SCHEMBL10239866 | 0.84 | FLT3 (0.54) | FLT3NRASIRAK4KDRCSF1R | |
| SCHEMBL376386 | 0.82 | IRAK4 (0.43) | FLT3NRASIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | FLT3 496/4885NRAS 1025/4885IRAK4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.